Rhumbline Advisers Phathom Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 50,858 shares of PHAT stock, worth $475,013. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,858
Previous 55,178 7.83%
Holding current value
$475,013
Previous $568,000 61.8%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$10.25 - $19.5 $44,280 - $84,240
-4,320 Reduced 7.83%
50,858 $919,000
Q2 2024

Aug 01, 2024
BUY
$8.97 - $12.05 $72,432 - $97,303
8,075 Added 17.14%
55,178 $568,000
Q1 2024

May 09, 2024
SELL
$6.21 - $11.05 $8,687 - $15,458
-1,399 Reduced 2.88%
47,103 $500,000
Q4 2023

Feb 08, 2024
SELL
$6.99 - $10.71 $56,164 - $86,054
-8,035 Reduced 14.21%
48,502 $442,000
Q3 2023

Nov 09, 2023
BUY
$10.26 - $15.7 $64,966 - $99,412
6,332 Added 12.61%
56,537 $586,000
Q2 2023

Aug 08, 2023
BUY
$7.28 - $14.32 $126,992 - $249,798
17,444 Added 53.25%
50,205 $718,000
Q1 2023

May 11, 2023
BUY
$6.19 - $12.36 $12,559 - $25,078
2,029 Added 6.6%
32,761 $234,000
Q4 2022

Feb 14, 2023
BUY
$9.18 - $11.53 $16,569 - $20,811
1,805 Added 6.24%
30,732 $345,000
Q3 2022

Nov 10, 2022
BUY
$6.46 - $12.11 $14,715 - $27,586
2,278 Added 8.55%
28,927 $321,000
Q2 2022

Aug 11, 2022
BUY
$6.2 - $15.5 $41,422 - $103,555
6,681 Added 33.46%
26,649 $225,000
Q1 2022

May 12, 2022
BUY
$11.55 - $20.06 $31,889 - $55,385
2,761 Added 16.05%
19,968 $272,000
Q4 2021

Feb 10, 2022
SELL
$17.83 - $33.15 $4,404 - $8,188
-247 Reduced 1.42%
17,207 $338,000
Q3 2021

Nov 12, 2021
BUY
$30.69 - $36.83 $31,181 - $37,419
1,016 Added 6.18%
17,454 $560,000
Q2 2021

Aug 05, 2021
BUY
$32.66 - $39.87 $164,867 - $201,263
5,048 Added 44.32%
16,438 $556,000
Q1 2021

May 06, 2021
SELL
$33.86 - $48.68 $27,426 - $39,430
-810 Reduced 6.64%
11,390 $428,000
Q4 2020

Feb 10, 2021
BUY
$33.22 - $50.26 $42,521 - $64,332
1,280 Added 11.72%
12,200 $405,000
Q3 2020

Nov 12, 2020
SELL
$29.24 - $40.19 $54,678 - $75,155
-1,870 Reduced 14.62%
10,920 $400,000
Q2 2020

Aug 13, 2020
BUY
$25.06 - $54.6 $34,257 - $74,638
1,367 Added 11.97%
12,790 $421,000
Q1 2020

May 06, 2020
BUY
$24.65 - $42.83 $109,372 - $190,036
4,437 Added 63.51%
11,423 $295,000
Q4 2019

Feb 05, 2020
BUY
$18.59 - $37.67 $129,869 - $263,162
6,986 New
6,986 $218,000

Others Institutions Holding PHAT

# of Institutions
144
Shares Held
73.6M
Call Options Held
42.3K
Put Options Held
45.7K
View Full List

About Phathom Pharmaceuticals, Inc.

PHAT Quotes by TradingView
  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $366M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email